<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00998985</url>
  </required_header>
  <id_info>
    <org_study_id>5172-004</org_study_id>
    <secondary_id>2009_678</secondary_id>
    <secondary_id>2009-015563-13</secondary_id>
    <nct_id>NCT00998985</nct_id>
  </id_info>
  <brief_title>A Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Male Participants (MK-5172-004)</brief_title>
  <official_title>A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Grazoprevir (MK-5172) in Hepatitis C Infected Male Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multiple dose study will assess the safety, tolerability, pharmacokinetics and
      pharmacodynamics of grazoprevir (MK-5172) in Genotype (GT) 1 and GT3 Hepatitis C virus (HCV)-
      infected participants. The primary hypothesis is that administration of grazoprevir for 7
      days is sufficiently safe and well tolerated in HCV-infected males.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Clinical and Laboratory Adverse Events (AEs)</measure>
    <time_frame>All AEs: 15 Days after last dose; Serious AEs (SAEs) up to 2 months after last dose (Up to 67 days)</time_frame>
    <description>An AE is any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR's product, is also an AE.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve for 0 to 24 Hours Post-dose (AUC[0-24hr]) of Grazoprevir on Day 7</measure>
    <time_frame>Day 7 at the following time points: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, and 24 hours post-dose</time_frame>
    <description>Blood samples were collected on Day 7 at pre-dose up to 24 hours post-dose in order to determine the AUC 0-24hrs of Grazoprevir. It is hypothesized that the Geometric Mean of Day 7 Grazoprevir AUC0-24hr. exceeds 3.2 uM.hr.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 Hour Plasma Concentration (C[24hr]) of Grazoprevir on Day 7</measure>
    <time_frame>Day 7 at 24 hours post-dose</time_frame>
    <description>Blood samples were collected on Day 7 at 24 hours post-dose in order to determine the C24hr of Grazoprevir. It is hypothesized that the Geometric Mean of Day 7 Grazoprevir C24hr exceeds 28 nM.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum log10 HCV RNA Reduction From Baseline Following Administration of Grazoprevir in Participants With GT1 HCV or Pooled GT1 and GT3 HCV Participants Treated With Placebo</measure>
    <time_frame>Baseline and up to approximately 2 months</time_frame>
    <description>Blood samples were collected at baseline and at intervals up to 2 months post-dose in order to determine the maximum log10 reduction from baseline in plasma HCV RNA, expressed in international units (IU)/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum log10 HCV RNA Reduction From Baseline Following Administration of Grazoprevir in Participants With GT3 HCV or Pooled GT1 and GT3 HCV Participants Treated With Placebo</measure>
    <time_frame>Baseline and up to approximately 2 months</time_frame>
    <description>Blood samples were collected at baseline and at intervals up to 2 months post-dose in order to determine the maximum log10 reduction from baseline in plasma HCV RNA.</description>
  </secondary_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>400 mg Grazoprevir - GT1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GT1 HCV-infected Participants: 400 mg Grazoprevir or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>600 mg Grazoprevir - GT1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GT1 HCV-infected Participants: 600 mg Grazoprevir or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>800 mg Grazoprevir - GT1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GT1 HCV-infected Participants: 800 mg Grazoprevir or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>400 mg Grazoprevir - GT3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GT3 HCV-infected Participants: 400 mg Grazoprevir or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>600 mg Grazoprevir - GT3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GT3 HCV-infected Participants: 600 mg Grazoprevir or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>800 mg Grazoprevir - GT3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GT3 HCV-infected Participants: 800 mg Grazoprevir or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg Grazoprevir - GT1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GT1 HCV-infected Participants: 200 mg Grazoprevir or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg Grazoprevir - GT1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GT1 HCV-infected Participants: 100 mg Grazoprevir or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 mg Grazoprevir - GT1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GT1 HCV-infected Participants: 50 mg Grazoprevir or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg Grazoprevir - GT3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GT3 HCV-infected Participants: 200 mg Grazoprevir or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg Grazoprevir - GT3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GT3 HCV-infected Participants: 100 mg Grazoprevir or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 mg Grazoprevir - GT3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GT3 HCV-infected Participants: 50 mg Grazoprevir or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mg Grazoprevir - GT1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GT1 HCV-infected Participants: 30 mg Grazoprevir or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg Grazoprevir - GT1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GT1 HCV-infected Participants: 10 mg Grazoprevir or Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Grazoprevir</intervention_name>
    <description>10, 30, 50, 100, 200, 400, 600 or 800 mg Grazoprevir tablets, orally, once a day for 7 days</description>
    <arm_group_label>400 mg Grazoprevir - GT1</arm_group_label>
    <arm_group_label>600 mg Grazoprevir - GT1</arm_group_label>
    <arm_group_label>800 mg Grazoprevir - GT1</arm_group_label>
    <arm_group_label>400 mg Grazoprevir - GT3</arm_group_label>
    <arm_group_label>600 mg Grazoprevir - GT3</arm_group_label>
    <arm_group_label>800 mg Grazoprevir - GT3</arm_group_label>
    <arm_group_label>200 mg Grazoprevir - GT1</arm_group_label>
    <arm_group_label>100 mg Grazoprevir - GT1</arm_group_label>
    <arm_group_label>50 mg Grazoprevir - GT1</arm_group_label>
    <arm_group_label>200 mg Grazoprevir - GT3</arm_group_label>
    <arm_group_label>100 mg Grazoprevir - GT3</arm_group_label>
    <arm_group_label>50 mg Grazoprevir - GT3</arm_group_label>
    <arm_group_label>30 mg Grazoprevir - GT1</arm_group_label>
    <arm_group_label>10 mg Grazoprevir - GT1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet, orally, once a day for 7 days</description>
    <arm_group_label>400 mg Grazoprevir - GT1</arm_group_label>
    <arm_group_label>600 mg Grazoprevir - GT1</arm_group_label>
    <arm_group_label>800 mg Grazoprevir - GT1</arm_group_label>
    <arm_group_label>400 mg Grazoprevir - GT3</arm_group_label>
    <arm_group_label>600 mg Grazoprevir - GT3</arm_group_label>
    <arm_group_label>800 mg Grazoprevir - GT3</arm_group_label>
    <arm_group_label>200 mg Grazoprevir - GT1</arm_group_label>
    <arm_group_label>100 mg Grazoprevir - GT1</arm_group_label>
    <arm_group_label>50 mg Grazoprevir - GT1</arm_group_label>
    <arm_group_label>200 mg Grazoprevir - GT3</arm_group_label>
    <arm_group_label>100 mg Grazoprevir - GT3</arm_group_label>
    <arm_group_label>50 mg Grazoprevir - GT3</arm_group_label>
    <arm_group_label>30 mg Grazoprevir - GT1</arm_group_label>
    <arm_group_label>10 mg Grazoprevir - GT1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Baseline health is stable.

          -  Has a clinical diagnosis of chronic HCV infection.

        Exclusion Criteria:

          -  Has a history of stroke or chronic seizures.

          -  Has a history of cancer.

          -  Has a history of human immunodeficiency virus (HIV) infection.

          -  Has had major surgery, donated blood or participated in another investigational study
             within the past 3 months.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Germany</country>
    <country>Russian Federation</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2009</study_first_submitted>
  <study_first_submitted_qc>October 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2009</study_first_posted>
  <results_first_submitted>February 3, 2016</results_first_submitted>
  <results_first_submitted_qc>February 3, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 2, 2016</results_first_posted>
  <last_update_submitted>March 1, 2017</last_update_submitted>
  <last_update_submitted_qc>March 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/study.html?id=5172-004&amp;kw=5172-004&amp;tab=access</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>One of the originally planned treatment groups (50 mg Grazoprevir - GT3) was not conducted because other results indicated that further evaluation of 50 mg Grazoprevir in GT3 participants was not necessary. It is therefore not included in the Participant Flow.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>400 mg Grazoprevir - GT1</title>
          <description>GT1 HCV-infected Participants: 400 mg Grazoprevir orally, once daily for 7 consecutive days</description>
        </group>
        <group group_id="P2">
          <title>600 mg Grazoprevir - GT1</title>
          <description>GT1 HCV-infected Participants: 600 mg Grazoprevir orally, once daily for 7 consecutive days</description>
        </group>
        <group group_id="P3">
          <title>800 mg Grazoprevir - GT1</title>
          <description>GT1 HCV-infected Participants: 800 mg Grazoprevir orally, once daily for 7 consecutive days</description>
        </group>
        <group group_id="P4">
          <title>400 mg Grazoprevir - GT3</title>
          <description>GT3 HCV-infected Participants: 400 mg Grazoprevir orally, once daily for 7 consecutive days</description>
        </group>
        <group group_id="P5">
          <title>600 mg Grazoprevir - GT3</title>
          <description>GT3 HCV-infected Participants: 600 mg Grazoprevir orally, once daily for 7 consecutive days</description>
        </group>
        <group group_id="P6">
          <title>800 mg Grazoprevir - GT3</title>
          <description>GT3 HCV-infected Participants: 800 mg Grazoprevir orally, once daily for 7 consecutive days</description>
        </group>
        <group group_id="P7">
          <title>200 mg Grazoprevir - GT1</title>
          <description>GT1 HCV-infected Participants: 200 mg Grazoprevir orally, once daily for 7 consecutive days</description>
        </group>
        <group group_id="P8">
          <title>100 mg Grazoprevir - GT1</title>
          <description>GT1 HCV-infected Participants: 100 mg Grazoprevir orally, once daily for 7 consecutive days</description>
        </group>
        <group group_id="P9">
          <title>50 mg Grazoprevir - GT1</title>
          <description>GT1 HCV-infected Participants: 50 mg Grazoprevir orally, once daily for 7 consecutive days</description>
        </group>
        <group group_id="P10">
          <title>200 mg Grazoprevir - GT3</title>
          <description>GT3 HCV-infected Participants: 200 mg Grazoprevir orally, once daily for 7 consecutive days</description>
        </group>
        <group group_id="P11">
          <title>100 mg Grazoprevir - GT3</title>
          <description>GT3 HCV-infected Participants: 100 mg Grazoprevir orally, once daily for 7 consecutive days</description>
        </group>
        <group group_id="P12">
          <title>30 mg Grazoprevir - GT1</title>
          <description>GT1 HCV-infected Participants: 30 mg Grazoprevir orally, once daily for 7 consecutive days</description>
        </group>
        <group group_id="P13">
          <title>10 mg Grazoprevir - GT1</title>
          <description>GT1 HCV-infected Participants: 10 mg Grazoprevir orally, once daily for 7 consecutive days</description>
        </group>
        <group group_id="P14">
          <title>Placebo for Grazoprevir - GT1 and GT3</title>
          <description>GT1 and GT3 HCV-infected Participants: Placebo for Grazoprevir orally, once daily for 7 consecutive days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="5"/>
                <participants group_id="P11" count="5"/>
                <participants group_id="P12" count="5"/>
                <participants group_id="P13" count="5"/>
                <participants group_id="P14" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="5"/>
                <participants group_id="P11" count="5"/>
                <participants group_id="P12" count="5"/>
                <participants group_id="P13" count="5"/>
                <participants group_id="P14" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants</population>
      <group_list>
        <group group_id="B1">
          <title>400 mg Grazoprevir - GT1</title>
          <description>GT1 HCV-infected Participants: 400 mg Grazoprevir orally, once daily for 7 consecutive days</description>
        </group>
        <group group_id="B2">
          <title>600 mg Grazoprevir - GT1</title>
          <description>GT1 HCV-infected Participants: 600 mg Grazoprevir orally, once daily for 7 consecutive days</description>
        </group>
        <group group_id="B3">
          <title>800 mg Grazoprevir - GT1</title>
          <description>GT1 HCV-infected Participants: 800 mg Grazoprevir orally, once daily for 7 consecutive days</description>
        </group>
        <group group_id="B4">
          <title>400 mg Grazoprevir - GT3</title>
          <description>GT3 HCV-infected Participants: 400 mg Grazoprevir orally, once daily for 7 consecutive days</description>
        </group>
        <group group_id="B5">
          <title>600 mg Grazoprevir - GT3</title>
          <description>GT3 HCV-infected Participants: 600 mg Grazoprevir orally, once daily for 7 consecutive days</description>
        </group>
        <group group_id="B6">
          <title>800 mg Grazoprevir - GT3</title>
          <description>GT3 HCV-infected Participants: 800 mg Grazoprevir orally, once daily for 7 consecutive days</description>
        </group>
        <group group_id="B7">
          <title>200 mg Grazoprevir - GT1</title>
          <description>GT1 HCV-infected Participants: 200 mg Grazoprevir orally, once daily for 7 consecutive days</description>
        </group>
        <group group_id="B8">
          <title>100 mg Grazoprevir - GT1</title>
          <description>GT1 HCV-infected Participants: 100 mg Grazoprevir orally, once daily for 7 consecutive days</description>
        </group>
        <group group_id="B9">
          <title>50 mg Grazoprevir - GT1</title>
          <description>GT1 HCV-infected Participants: 50 mg Grazoprevir orally, once daily for 7 consecutive days</description>
        </group>
        <group group_id="B10">
          <title>200 mg Grazoprevir - GT3</title>
          <description>GT3 HCV-infected Participants: 200 mg Grazoprevir orally, once daily for 7 consecutive days</description>
        </group>
        <group group_id="B11">
          <title>100 mg Grazoprevir - GT3</title>
          <description>GT3 HCV-infected Participants: 100 mg Grazoprevir orally, once daily for 7 consecutive days</description>
        </group>
        <group group_id="B12">
          <title>30 mg Grazoprevir - GT1</title>
          <description>GT1 HCV-infected Participants: 30 mg Grazoprevir orally, once daily for 7 consecutive days</description>
        </group>
        <group group_id="B13">
          <title>10 mg Grazoprevir - GT1</title>
          <description>GT1 HCV-infected Participants: 10 mg Grazoprevir orally, once daily for 7 consecutive days</description>
        </group>
        <group group_id="B14">
          <title>Placebo for Grazoprevir - GT1 and GT3</title>
          <description>GT1 and GT3 HCV-infected Participants: Placebo for Grazoprevir orally, once daily for 7 consecutive days</description>
        </group>
        <group group_id="B15">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="15"/>
            <count group_id="B4" value="5"/>
            <count group_id="B5" value="5"/>
            <count group_id="B6" value="5"/>
            <count group_id="B7" value="5"/>
            <count group_id="B8" value="5"/>
            <count group_id="B9" value="6"/>
            <count group_id="B10" value="5"/>
            <count group_id="B11" value="5"/>
            <count group_id="B12" value="5"/>
            <count group_id="B13" value="5"/>
            <count group_id="B14" value="15"/>
            <count group_id="B15" value="91"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.4" spread="12.8"/>
                    <measurement group_id="B2" value="47.2" spread="12.2"/>
                    <measurement group_id="B3" value="46.7" spread="9.7"/>
                    <measurement group_id="B4" value="42.8" spread="14.4"/>
                    <measurement group_id="B5" value="38.0" spread="13.1"/>
                    <measurement group_id="B6" value="46.2" spread="10.8"/>
                    <measurement group_id="B7" value="51.0" spread="16.2"/>
                    <measurement group_id="B8" value="48.4" spread="5.9"/>
                    <measurement group_id="B9" value="36.8" spread="6.0"/>
                    <measurement group_id="B10" value="40.0" spread="10.2"/>
                    <measurement group_id="B11" value="31.4" spread="6.3"/>
                    <measurement group_id="B12" value="55.8" spread="5.4"/>
                    <measurement group_id="B13" value="48.4" spread="13.1"/>
                    <measurement group_id="B14" value="45.6" spread="11.5"/>
                    <measurement group_id="B15" value="44.7" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="5"/>
                    <measurement group_id="B11" value="5"/>
                    <measurement group_id="B12" value="5"/>
                    <measurement group_id="B13" value="5"/>
                    <measurement group_id="B14" value="15"/>
                    <measurement group_id="B15" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinical and Laboratory Adverse Events (AEs)</title>
        <description>An AE is any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR’s product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR’s product, is also an AE.</description>
        <time_frame>All AEs: 15 Days after last dose; Serious AEs (SAEs) up to 2 months after last dose (Up to 67 days)</time_frame>
        <population>All participants who received at least one dose of the investigational drug according to the treatment(s) they actually received. Participants with either GT1 or GT3 who received the same treatment were combined for the summary into a single GT1 and GT3 arm.</population>
        <group_list>
          <group group_id="O1">
            <title>400 mg Grazoprevir - GT1 and GT3</title>
            <description>GT1 and GT3 HCV-infected Participants: 400 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O2">
            <title>600 mg Grazoprevir - GT1 and GT3</title>
            <description>GT1 and GT3 HCV-infected Participants: 600 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O3">
            <title>800 mg Grazoprevir - GT1 and GT3</title>
            <description>GT1 and GT3 HCV-infected Participants: 800 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O4">
            <title>200 mg Grazoprevir - GT1 and GT3</title>
            <description>GT1 and GT3 HCV-infected Participants: 200 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O5">
            <title>100 mg Grazoprevir - GT1 and GT3</title>
            <description>GT1 and GT3 HCV-infected Participants: 100 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O6">
            <title>50 mg Grazoprevir - GT1</title>
            <description>GT1 HCV-infected Participants: 50 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O7">
            <title>30 mg Grazoprevir - GT1</title>
            <description>GT1 HCV-infected Participants: 30 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O8">
            <title>10 mg Grazoprevir - GT1</title>
            <description>GT1 HCV-infected Participants: 10 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O9">
            <title>Placebo for Grazoprevir - GT1 and GT3</title>
            <description>GT1 and GT3 HCV-infected Participants: Placebo for Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical and Laboratory Adverse Events (AEs)</title>
          <description>An AE is any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR’s product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR’s product, is also an AE.</description>
          <population>All participants who received at least one dose of the investigational drug according to the treatment(s) they actually received. Participants with either GT1 or GT3 who received the same treatment were combined for the summary into a single GT1 and GT3 arm.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="5"/>
                <count group_id="O9" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve for 0 to 24 Hours Post-dose (AUC[0-24hr]) of Grazoprevir on Day 7</title>
        <description>Blood samples were collected on Day 7 at pre-dose up to 24 hours post-dose in order to determine the AUC 0-24hrs of Grazoprevir. It is hypothesized that the Geometric Mean of Day 7 Grazoprevir AUC0-24hr. exceeds 3.2 uM.hr.</description>
        <time_frame>Day 7 at the following time points: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, and 24 hours post-dose</time_frame>
        <population>Participants who complied with the protocol sufficiently to ensure that these data will exhibit the effects of treatment, according to the underlying scientific model. GT1 or GT3 participants who received the same treatment were combined into a single arm. Participants with placebo were not analyzed as they did not receive grazoprevir.</population>
        <group_list>
          <group group_id="O1">
            <title>400 mg Grazoprevir - GT1 and GT3</title>
            <description>GT1 and GT3 HCV-infected Participants: 400 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O2">
            <title>600 mg Grazoprevir - GT1 and GT3</title>
            <description>GT1 and GT3 HCV-infected Participants: 600 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O3">
            <title>800 mg Grazoprevir - GT1 and GT3</title>
            <description>GT1 and GT3 HCV-infected Participants: 800 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O4">
            <title>200 mg Grazoprevir - GT1 and GT3</title>
            <description>GT1 and GT3 HCV-infected Participants: 200 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O5">
            <title>100 mg Grazoprevir - GT1 and GT3</title>
            <description>GT1 and GT3 HCV-infected Participants: 100 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O6">
            <title>50 mg Grazoprevir - GT1</title>
            <description>GT1 HCV-infected Participants: 50 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O7">
            <title>30 mg Grazoprevir - GT1</title>
            <description>GT1 HCV-infected Participants: 30 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O8">
            <title>10 mg Grazoprevir - GT1</title>
            <description>GT1 HCV-infected Participants: 10 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O9">
            <title>Placebo for Grazoprevir - GT1 and GT3</title>
            <description>GT1 and GT3 HCV-infected Participants: Placebo for Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve for 0 to 24 Hours Post-dose (AUC[0-24hr]) of Grazoprevir on Day 7</title>
          <description>Blood samples were collected on Day 7 at pre-dose up to 24 hours post-dose in order to determine the AUC 0-24hrs of Grazoprevir. It is hypothesized that the Geometric Mean of Day 7 Grazoprevir AUC0-24hr. exceeds 3.2 uM.hr.</description>
          <population>Participants who complied with the protocol sufficiently to ensure that these data will exhibit the effects of treatment, according to the underlying scientific model. GT1 or GT3 participants who received the same treatment were combined into a single arm. Participants with placebo were not analyzed as they did not receive grazoprevir.</population>
          <units>uM.hr</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="5"/>
                <count group_id="O9" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2" lower_limit="12.2" upper_limit="27.2"/>
                    <measurement group_id="O2" value="41.9" lower_limit="28.0" upper_limit="62.6"/>
                    <measurement group_id="O3" value="72.5" lower_limit="54.1" upper_limit="97.2"/>
                    <measurement group_id="O4" value="3.21" lower_limit="2.14" upper_limit="4.80"/>
                    <measurement group_id="O5" value="1.16" lower_limit="0.774" upper_limit="1.73"/>
                    <measurement group_id="O6" value="0.419" lower_limit="0.237" upper_limit="0.740"/>
                    <measurement group_id="O7" value="0.260" lower_limit="0.147" upper_limit="0.459"/>
                    <measurement group_id="O8" value="0.0628" lower_limit="0.0355" upper_limit="0.111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>24 Hour Plasma Concentration (C[24hr]) of Grazoprevir on Day 7</title>
        <description>Blood samples were collected on Day 7 at 24 hours post-dose in order to determine the C24hr of Grazoprevir. It is hypothesized that the Geometric Mean of Day 7 Grazoprevir C24hr exceeds 28 nM.</description>
        <time_frame>Day 7 at 24 hours post-dose</time_frame>
        <population>Participants who complied with the protocol sufficiently to ensure that these data will exhibit the effects of treatment, according to the underlying scientific model. GT1 or GT3 participants who received the same treatment were combined into a single arm. Participants with placebo were not analyzed as they did not receive grazoprevir.</population>
        <group_list>
          <group group_id="O1">
            <title>400 mg Grazoprevir - GT1 and GT3</title>
            <description>GT1 and GT3 HCV-infected Participants: 400 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O2">
            <title>600 mg Grazoprevir - GT1 and GT3</title>
            <description>GT1 and GT3 HCV-infected Participants: 600 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O3">
            <title>800 mg Grazoprevir - GT1 and GT3</title>
            <description>GT1 and GT3 HCV-infected Participants: 800 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O4">
            <title>200 mg Grazoprevir - GT1 and GT3</title>
            <description>GT1 and GT3 HCV-infected Participants: 200 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O5">
            <title>100 mg Grazoprevir - GT1 and GT3</title>
            <description>GT1 and GT3 HCV-infected Participants: 100 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O6">
            <title>50 mg Grazoprevir - GT1</title>
            <description>GT1 HCV-infected Participants: 50 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O7">
            <title>30 mg Grazoprevir - GT1</title>
            <description>GT1 HCV-infected Participants: 30 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O8">
            <title>10 mg Grazoprevir - GT1</title>
            <description>GT1 HCV-infected Participants: 10 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O9">
            <title>Placebo for Grazoprevir - GT1 and GT3</title>
            <description>GT1 and GT3 HCV-infected Participants: Placebo for Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>24 Hour Plasma Concentration (C[24hr]) of Grazoprevir on Day 7</title>
          <description>Blood samples were collected on Day 7 at 24 hours post-dose in order to determine the C24hr of Grazoprevir. It is hypothesized that the Geometric Mean of Day 7 Grazoprevir C24hr exceeds 28 nM.</description>
          <population>Participants who complied with the protocol sufficiently to ensure that these data will exhibit the effects of treatment, according to the underlying scientific model. GT1 or GT3 participants who received the same treatment were combined into a single arm. Participants with placebo were not analyzed as they did not receive grazoprevir.</population>
          <units>nM</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="5"/>
                <count group_id="O9" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.2" lower_limit="46.9" upper_limit="105"/>
                    <measurement group_id="O2" value="93.2" lower_limit="62.3" upper_limit="140"/>
                    <measurement group_id="O3" value="174" lower_limit="130" upper_limit="233"/>
                    <measurement group_id="O4" value="22.2" lower_limit="14.8" upper_limit="33.2"/>
                    <measurement group_id="O5" value="20.1" lower_limit="13.4" upper_limit="30.1"/>
                    <measurement group_id="O6" value="12.7" lower_limit="7.16" upper_limit="22.4"/>
                    <measurement group_id="O7" value="7.20" lower_limit="4.07" upper_limit="12.7"/>
                    <measurement group_id="O8" value="2.41" lower_limit="1.36" upper_limit="4.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum log10 HCV RNA Reduction From Baseline Following Administration of Grazoprevir in Participants With GT1 HCV or Pooled GT1 and GT3 HCV Participants Treated With Placebo</title>
        <description>Blood samples were collected at baseline and at intervals up to 2 months post-dose in order to determine the maximum log10 reduction from baseline in plasma HCV RNA, expressed in international units (IU)/mL.</description>
        <time_frame>Baseline and up to approximately 2 months</time_frame>
        <population>Participants who complied with the protocol sufficiently to ensure that these data will exhibit the effects of treatment, according to the underlying scientific model. One GT1 participant treated with 50 mg grazoprevir, who discontinued, and all GT3 participants treated with grazoprevir were excluded from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>400 mg Grazoprevir - GT1</title>
            <description>GT1 HCV-infected Participants: 400 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O2">
            <title>600 mg Grazoprevir - GT1</title>
            <description>GT1 HCV-infected Participants: 600 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O3">
            <title>800 mg Grazoprevir - GT1</title>
            <description>GT1 HCV-infected Participants: 800 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O4">
            <title>200 mg Grazoprevir - GT1</title>
            <description>GT1 HCV-infected Participants: 200 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O5">
            <title>100 mg Grazoprevir - GT1</title>
            <description>GT1 HCV-infected Participants: 100 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O6">
            <title>50 mg Grazoprevir - GT1</title>
            <description>GT1 HCV-infected Participants: 50 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O7">
            <title>30 mg Grazoprevir - GT1</title>
            <description>GT1 HCV-infected Participants: 30 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O8">
            <title>10 mg Grazoprevir - GT1</title>
            <description>GT1 HCV-infected Participants: 10 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O9">
            <title>Placebo for Grazoprevir - GT1 and GT3</title>
            <description>Pooled GT1 and GT3 HCV-infected Participants: Placebo for Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O10">
            <title>400 mg Grazoprevir - GT3</title>
            <description>GT3 HCV-infected Participants: 400 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O11">
            <title>600 mg Grazoprevir - GT3</title>
            <description>GT3 HCV-infected Participants: 600 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O12">
            <title>800 mg Grazoprevir - GT3</title>
            <description>GT3 HCV-infected Participants: 800 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O13">
            <title>200 mg Grazoprevir - GT3</title>
            <description>GT3 HCV-infected Participants: 200 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O14">
            <title>100 mg Grazoprevir - GT3</title>
            <description>GT3 HCV-infected Participants: 100 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum log10 HCV RNA Reduction From Baseline Following Administration of Grazoprevir in Participants With GT1 HCV or Pooled GT1 and GT3 HCV Participants Treated With Placebo</title>
          <description>Blood samples were collected at baseline and at intervals up to 2 months post-dose in order to determine the maximum log10 reduction from baseline in plasma HCV RNA, expressed in international units (IU)/mL.</description>
          <population>Participants who complied with the protocol sufficiently to ensure that these data will exhibit the effects of treatment, according to the underlying scientific model. One GT1 participant treated with 50 mg grazoprevir, who discontinued, and all GT3 participants treated with grazoprevir were excluded from analysis.</population>
          <units>log10 IU/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="5"/>
                <count group_id="O9" value="15"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
                <count group_id="O13" value="0"/>
                <count group_id="O14" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.14" lower_limit="4.55" upper_limit="5.73"/>
                    <measurement group_id="O2" value="5.32" lower_limit="4.73" upper_limit="5.91"/>
                    <measurement group_id="O3" value="5.72" lower_limit="5.38" upper_limit="6.07"/>
                    <measurement group_id="O4" value="5.53" lower_limit="4.94" upper_limit="6.12"/>
                    <measurement group_id="O5" value="4.74" lower_limit="4.15" upper_limit="5.33"/>
                    <measurement group_id="O6" value="5.26" lower_limit="4.67" upper_limit="5.85"/>
                    <measurement group_id="O7" value="5.06" lower_limit="4.47" upper_limit="5.66"/>
                    <measurement group_id="O8" value="3.84" lower_limit="3.25" upper_limit="4.43"/>
                    <measurement group_id="O9" value="0.39" lower_limit="0.04" upper_limit="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>It is hypothesized that one or more doses of Grazoprevir will reduce GT1 viral load by at least 3 log10</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least Squares Mean (LSM) Difference</param_type>
            <param_value>3.46</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.89</ci_lower_limit>
            <ci_upper_limit>4.03</ci_upper_limit>
            <estimate_desc>LSM Difference (grazoprevir-placebo) and confidence intervals from ANOVA model with maximum log10 HCV reduction as response and a fixed effect for treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>It is hypothesized that one or more doses of Grazoprevir will reduce GT1 viral load by at least 3 log10</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LSM Difference</param_type>
            <param_value>4.68</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.11</ci_lower_limit>
            <ci_upper_limit>5.25</ci_upper_limit>
            <estimate_desc>LSM Difference (grazoprevir-placebo) and confidence intervals from ANOVA model with maximum log10 HCV reduction as response and a fixed effect for treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>It is hypothesized that one or more doses of Grazoprevir will reduce GT1 viral load by at least 3 log10</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LSM Difference</param_type>
            <param_value>4.87</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.30</ci_lower_limit>
            <ci_upper_limit>5.44</ci_upper_limit>
            <estimate_desc>LSM Difference (grazoprevir-placebo) and confidence intervals from ANOVA model with maximum log10 HCV reduction as response and a fixed effect for treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>It is hypothesized that one or more doses of Grazoprevir will reduce GT1 viral load by at least 3 log10</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LSM Difference</param_type>
            <param_value>4.35</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.78</ci_lower_limit>
            <ci_upper_limit>4.92</ci_upper_limit>
            <estimate_desc>LSM Difference (grazoprevir-placebo) and confidence intervals from ANOVA model with maximum log10 HCV reduction as response and a fixed effect for treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>It is hypothesized that one or more doses of Grazoprevir will reduce GT1 viral load by at least 3 log10</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LSM Difference</param_type>
            <param_value>5.15</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.58</ci_lower_limit>
            <ci_upper_limit>5.72</ci_upper_limit>
            <estimate_desc>LSM Difference (grazoprevir-placebo) and confidence intervals from ANOVA model with maximum log10 HCV reduction as response and a fixed effect for treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>It is hypothesized that one or more doses of Grazoprevir will reduce GT1 viral load by at least 3 log10</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LSM Difference</param_type>
            <param_value>4.76</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.19</ci_lower_limit>
            <ci_upper_limit>5.33</ci_upper_limit>
            <estimate_desc>LSM Difference (grazoprevir-placebo) and confidence intervals from ANOVA model with maximum log10 HCV reduction as response and a fixed effect for treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>It is hypothesized that one or more doses of Grazoprevir will reduce GT1 viral load by at least 3 log10</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LSM Difference</param_type>
            <param_value>4.93</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.36</ci_lower_limit>
            <ci_upper_limit>5.50</ci_upper_limit>
            <estimate_desc>LSM Difference (grazoprevir-placebo) and confidence intervals from ANOVA model with maximum log10 HCV reduction as response and a fixed effect for treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>It is hypothesized that one or more doses of Grazoprevir will reduce GT1 viral load by at least 3 log10</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LSM Difference</param_type>
            <param_value>5.34</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.93</ci_lower_limit>
            <ci_upper_limit>5.74</ci_upper_limit>
            <estimate_desc>LSM Difference (grazoprevir-placebo) and confidence intervals from ANOVA model with maximum log10 HCV reduction as response and a fixed effect for treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum log10 HCV RNA Reduction From Baseline Following Administration of Grazoprevir in Participants With GT3 HCV or Pooled GT1 and GT3 HCV Participants Treated With Placebo</title>
        <description>Blood samples were collected at baseline and at intervals up to 2 months post-dose in order to determine the maximum log10 reduction from baseline in plasma HCV RNA.</description>
        <time_frame>Baseline and up to approximately 2 months</time_frame>
        <population>Participants who complied with the protocol sufficiently to ensure that these data will exhibit the effects of treatment, according to the underlying scientific model. One GT3 participant treated with 800 mg grazoprevir, who discontinued, and all GT1 participants were excluded from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>400 mg Grazoprevir - GT3</title>
            <description>GT3 HCV-infected Participants: 400 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O2">
            <title>600 mg Grazoprevir - GT3</title>
            <description>GT3 HCV-infected Participants: 600 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O3">
            <title>800 mg Grazoprevir - GT3</title>
            <description>GT3 HCV-infected Participants: 800 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O4">
            <title>200 mg Grazoprevir - GT3</title>
            <description>GT3 HCV-infected Participants: 200 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O5">
            <title>100 mg Grazoprevir - GT3</title>
            <description>GT3 HCV-infected Participants: 100 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O6">
            <title>Placebo for Grazoprevir - GT1 and GT3</title>
            <description>Pooled GT1 and GT3 HCV-infected Participants: Placebo for Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O7">
            <title>800 mg Grazoprevir - GT1</title>
            <description>GT1 HCV-infected Participants: 800 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O8">
            <title>600 mg Grazoprevir - GT1</title>
            <description>GT1 HCV-infected Participants: 600 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O9">
            <title>400 mg Grazoprevir - GT1</title>
            <description>GT1 HCV-infected Participants: 400 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O10">
            <title>200 mg Grazoprevir - GT1</title>
            <description>GT1 HCV-infected Participants: 200 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O11">
            <title>100 mg Grazoprevir - GT1</title>
            <description>GT1 HCV-infected Participants: 100 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O12">
            <title>50 mg Grazoprevir - GT1</title>
            <description>GT1 HCV-infected Participants: 50 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O13">
            <title>30 mg Grazoprevir - GT1</title>
            <description>GT1 HCV-infected Participants: 30 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
          <group group_id="O14">
            <title>10 mg Grazoprevir - GT1</title>
            <description>GT1 HCV-infected Participants: 10 mg Grazoprevir orally, once daily for 7 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum log10 HCV RNA Reduction From Baseline Following Administration of Grazoprevir in Participants With GT3 HCV or Pooled GT1 and GT3 HCV Participants Treated With Placebo</title>
          <description>Blood samples were collected at baseline and at intervals up to 2 months post-dose in order to determine the maximum log10 reduction from baseline in plasma HCV RNA.</description>
          <population>Participants who complied with the protocol sufficiently to ensure that these data will exhibit the effects of treatment, according to the underlying scientific model. One GT3 participant treated with 800 mg grazoprevir, who discontinued, and all GT1 participants were excluded from analysis.</population>
          <units>log10 IU/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
                <count group_id="O13" value="0"/>
                <count group_id="O14" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.23" lower_limit="3.65" upper_limit="4.81"/>
                    <measurement group_id="O2" value="5.36" lower_limit="4.79" upper_limit="5.94"/>
                    <measurement group_id="O3" value="4.60" lower_limit="3.95" upper_limit="5.24"/>
                    <measurement group_id="O4" value="3.32" lower_limit="2.75" upper_limit="3.90"/>
                    <measurement group_id="O5" value="2.64" lower_limit="2.06" upper_limit="3.22"/>
                    <measurement group_id="O6" value="0.39" lower_limit="0.05" upper_limit="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>It is hypothesized that one or more doses of Grazoprevir will reduce GT3 viral load by at least 2 log10</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LSM Difference</param_type>
            <param_value>2.25</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.70</ci_lower_limit>
            <ci_upper_limit>2.81</ci_upper_limit>
            <estimate_desc>LSM Difference (grazoprevir-placebo) and confidence intervals from ANOVA model with maximum log10 HCV reduction as response and a fixed effect for treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>It is hypothesized that one or more doses of Grazoprevir will reduce GT3 viral load by at least 2 log10</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LSM Difference</param_type>
            <param_value>2.94</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.38</ci_lower_limit>
            <ci_upper_limit>3.49</ci_upper_limit>
            <estimate_desc>LSM Difference (grazoprevir-placebo) and confidence intervals from ANOVA model with maximum log10 HCV reduction as response and a fixed effect for treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>It is hypothesized that one or more doses of Grazoprevir will reduce GT3 viral load by at least 2 log10</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LSM Difference</param_type>
            <param_value>3.84</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.29</ci_lower_limit>
            <ci_upper_limit>4.40</ci_upper_limit>
            <estimate_desc>LSM Difference (grazoprevir-placebo) and confidence intervals from ANOVA model with maximum log10 HCV reduction as response and a fixed effect for treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>It is hypothesized that one or more doses of Grazoprevir will reduce GT3 viral load by at least 2 log10</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LSM difference</param_type>
            <param_value>4.98</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.42</ci_lower_limit>
            <ci_upper_limit>5.53</ci_upper_limit>
            <estimate_desc>LSM Difference (grazoprevir-placebo) and confidence intervals from ANOVA model with maximum log10 HCV reduction as response and a fixed effect for treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>It is hypothesized that one or more doses of Grazoprevir will reduce GT3 viral load by at least 2 log10</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LSM difference</param_type>
            <param_value>4.21</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.60</ci_lower_limit>
            <ci_upper_limit>4.81</ci_upper_limit>
            <estimate_desc>LSM Difference (grazoprevir-placebo) and confidence intervals from ANOVA model with maximum log10 HCV reduction as response and a fixed effect for treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All AEs: 15 Days after last dose; Serious AEs (SAEs) up to 2 months after last dose (Up to 67 days)</time_frame>
      <desc>All participants who received at least one dose of drug according to the treatment(s) they actually received. Participants with either GT1 or GT3 who received the same treatment are combined into a single GT1 and GT3 arm.</desc>
      <group_list>
        <group group_id="E1">
          <title>400 mg Grazoprevir - GT1 and GT3</title>
          <description>GT1 and GT3 HCV-infected Participants: 400 mg Grazoprevir orally, once daily for 7 consecutive days</description>
        </group>
        <group group_id="E2">
          <title>600 mg Grazoprevir - GT1 and GT3</title>
          <description>GT1 and GT3 HCV-infected Participants: 600 mg Grazoprevir orally, once daily for 7 consecutive days</description>
        </group>
        <group group_id="E3">
          <title>800 mg Grazoprevir - GT1 and GT3</title>
          <description>GT1 and GT3 HCV-infected Participants: 800 mg Grazoprevir orally, once daily for 7 consecutive days</description>
        </group>
        <group group_id="E4">
          <title>200 mg Grazoprevir - GT1 and GT3</title>
          <description>GT1 and GT3 HCV-infected Participants: 200 mg Grazoprevir orally, once daily for 7 consecutive days</description>
        </group>
        <group group_id="E5">
          <title>100 mg Grazoprevir - GT1 and GT3</title>
          <description>GT1 and GT3 HCV-infected Participants: 100 mg Grazoprevir orally, once daily for 7 consecutive days</description>
        </group>
        <group group_id="E6">
          <title>50 mg Grazoprevir - GT1</title>
          <description>GT1 HCV-infected Participants: 50 mg Grazoprevir orally, once daily for 7 consecutive days</description>
        </group>
        <group group_id="E7">
          <title>30 mg Grazoprevir - GT1</title>
          <description>GT1 HCV-infected Participants: 30 mg Grazoprevir orally, once daily for 7 consecutive days</description>
        </group>
        <group group_id="E8">
          <title>10 mg Grazoprevir - GT1</title>
          <description>GT1 HCV-infected Participants: 10 mg Grazoprevir orally, once daily for 7 consecutive days</description>
        </group>
        <group group_id="E9">
          <title>Placebo for Grazoprevir - GT1 and GT3</title>
          <description>GT1 and GT3 HCV-infected Participants: Placebo for Grazoprevir orally, once daily for 7 consecutive days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="10" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="11" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="3" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Macule</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

